MARKET

VERU

VERU

VERU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.42
+0.17
+1.84%
After Hours: 9.40 -0.02 -0.21% 19:48 04/16 EDT
OPEN
9.25
PREV CLOSE
9.25
HIGH
9.54
LOW
8.82
VOLUME
2.11M
TURNOVER
--
52 WEEK HIGH
24.57
52 WEEK LOW
2.300
MARKET CAP
738.14M
P/E (TTM)
47100.00
1D
5D
1M
3M
1Y
5Y
2 Strong Buy Stocks Around $10 With Triple-Digit Upside Potential
TipRanks · 1d ago
Thinking about buying stock in IZEA Worldwide, WiMi Hologram Cloud, Veru, iHeartMedia, or Supernus Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IZEA, WIMI, VERU, IHRT, and SUPN.
PR Newswire - PRF · 4d ago
DJ Veru Initiated at Buy by Jefferies
Dow Jones · 4d ago
DJ Veru Price Target Announced at $19.00/Share by Jefferies
Dow Jones · 4d ago
Veritone Extends Agreement With Audacy
The agreement equips Audacy's 235+ stations nationwide with the ability to seamlessly ingest, index, organize and analyze its media Veritone, Inc. (NASDAQ:VERI), the creator of the world's first operating system
Benzinga · 4d ago
Condom Market Global Analysis, Top Key Players, Growing Demand, Regional Trends and Forecast to 2027 | Fortune Business Insights
Apr 06, 2021 (The Expresswire) -- The global condom market size is expected to reach USD 9.90 billion by 2027, exhibiting a CAGR of 9.3% during the forecast...
The Express Wire · 04/06 09:41
Are Options Traders Betting on a Big Move in Veru (VERU) Stock?
Zacks.com · 04/05 12:02
Contraceptive Market Segmentation, Manufacturing Cost Analysis Including Key Raw Materials, Price Trend, Key Suppliers and Forecast 2029 | Bayer AGPfizer Inc., Janssen Global Services, LLC, Teva Pharmaceutical Industries Ltd.
Apr 02, 2021 (MARKITWIRED via COMTEX) -- The global contraceptives market size is expected to reach ~US$ 33,529 Mn by the end of 2029. According to a study...
Markitwired · 04/02 09:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VERU. Analyze the recent business situations of VERU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VERU stock price target is 23.60 with a high estimate of 30.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 19.80M
% Owned: 25.26%
Shares Outstanding: 78.36M
TypeInstitutionsShares
Increased
34
3.37M
New
22
2.60M
Decreased
19
1.67M
Sold Out
6
929.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Personal Products
+0.33%
Personal & Household Products & Services
+0.34%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mitchell Steiner
Vice Chairman/Director
Harry Fisch
Chief Financial Officer/Chief Administrative Officer
Michele Greco
Chief Scientific Officer
K. Gary Barnette
Chief Scientific Officer
K Barnette
Chief Scientific Officer
K. Barnette
Independent Director
Mario Eisenberger
Independent Director
Grace Hyun
Independent Director
Michael Rankowitz
Independent Director
Jesus Socorro
Declaration Date
Dividend Per Share
Ex-Div Date
03/24/2014
Dividend USD 0.07
04/28/2014
12/16/2013
Dividend USD 0.07
01/27/2014
10/03/2013
Dividend USD 0.07
10/28/2013
07/15/2013
Dividend USD 0.07
07/29/2013
03/27/2013
Dividend USD 0.07
04/29/2013
01/03/2013
Dividend USD 0.06
01/28/2013
10/04/2012
Dividend USD 0.06
10/29/2012
07/13/2012
Dividend USD 0.06
07/30/2012
03/27/2012
Dividend USD 0.06
04/30/2012
01/04/2012
Dividend USD 0.05
01/30/2012
10/06/2011
Dividend USD 0.05
10/31/2011
07/14/2011
Dividend USD 0.05
07/29/2011
04/11/2011
Dividend USD 0.05
04/29/2011
01/14/2011
Dividend USD 0.05
01/27/2011
10/08/2010
Dividend USD 0.05
11/01/2010
07/22/2010
Dividend USD 0.05
08/02/2010
--
Dividend USD 0.05
04/21/2010
01/14/2010
Dividend USD 0.05
01/27/2010
About VERU
Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing medicines for the management of prostate cancer. The Company operates in two segments: Commercial and Research, and Development. The Commercial segment consists of FC2. The Research and Development segment consists of multiple drug products under clinical development for oncology and urology. The Company's prostate cancer pipeline includes VERU-111, VERU-100 and Zuclomiphene Citrate. VERU-111 is an oral chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules. VERU-100 is a peptide formulation designed to address the limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. The Company's commercial products include FC2 Female Condom/FC2 Internal Condom (FC2), a product for the protection against unintended pregnancy and sexually transmitted infections.

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.